AIM: This study was designed to investigate the prognostic value of the neutrophil:lymphocyte ratio (NLR) in cervical cancer. PATIENTS AND METHODS: Patients with clinically staged cervical carcinoma (IB to IVA) at Samsung Medical Center, Seoul, Korea, from 1996 to 2007 were retrospectively enrolled. RESULTS: We enrolled 1061 patients with cervical cancer. The median NLR was 1.9, with a range of 0.3-27.0. When the cohort was divided according to the median NLR, poorer survival outcomes were observed in the group with higher NLR (≥1.9) than in the lower NLR group (<1.9). Patients of the higher NLR group (≥1.9) were younger in age and had more advanced staged disease when compared with those of the lower NLR group (<1.9). In multivariable analysis, higher pretreatment NLR was identified as being an independent poor prognostic factor for survival. CONCLUSION: Pretreatment NLR may be a cost-effective biomarker to stratify risk of recurrence and death in patients with cervical cancer.
AIM: This study was designed to investigate the prognostic value of the neutrophil:lymphocyte ratio (NLR) in cervical cancer. PATIENTS AND METHODS: Patients with clinically staged cervical carcinoma (IB to IVA) at Samsung Medical Center, Seoul, Korea, from 1996 to 2007 were retrospectively enrolled. RESULTS: We enrolled 1061 patients with cervical cancer. The median NLR was 1.9, with a range of 0.3-27.0. When the cohort was divided according to the median NLR, poorer survival outcomes were observed in the group with higher NLR (≥1.9) than in the lower NLR group (<1.9). Patients of the higher NLR group (≥1.9) were younger in age and had more advanced staged disease when compared with those of the lower NLR group (<1.9). In multivariable analysis, higher pretreatment NLR was identified as being an independent poor prognostic factor for survival. CONCLUSION: Pretreatment NLR may be a cost-effective biomarker to stratify risk of recurrence and death in patients with cervical cancer.
Authors: Alicia-Marie Conway; Zena Salih; George Papaxoinis; Kimberly Fletcher; Jamie Weaver; Ana Patrao; Robert Noble; Sofia Stamatopoulou; Vikki Owen-Holt; Wasat Mansoor Journal: Med Oncol Date: 2017-05-12 Impact factor: 3.064
Authors: Jonathan Cools-Lartigue; Jonathan Spicer; Braedon McDonald; Stephen Gowing; Simon Chow; Betty Giannias; France Bourdeau; Paul Kubes; Lorenzo Ferri Journal: J Clin Invest Date: 2013-07-01 Impact factor: 14.808